Literature DB >> 20150642

CpG island promoter methylation (CIHM) status of tumor suppressor genes correlates with morphological appearances of gastric cancer.

Tomomitsu Tahara1, Tomoyuki Shibata, Tomiyasu Arisawa, Masakatsu Nakamura, Hiromi Yamashita, Daisuke Yoshioka, Masaaki Okubo, Joh Yonemura, Yoshiteru Maeda, Naoko Maruyama, Toshiaki Kamano, Yoshio Kamiya, Hiroshi Fujita, Yoshihito Nakagawa, Mitsuo Nagasaka, Masami Iwata, Ichiro Hirata.   

Abstract

UNLABELLED: CpG island hypermethylation (CIHM) of tumor suppressor genes is one of the major events in the gastric carcinogenesis. We aimed to investigate the association between CIHM status of tumor suppressor genes and clinicopathological and morphological characteristics of gastric cancer. PATIENTS AND METHODS: CIHM of p14, p16, Death-associated protein kinase (DAPK) and E-cadherin (CDH1) genes were determined by methylation-specific-polymerase chain Reaction in 146 gastric cancer tissues. CIHM-high was defined as three or more methylated CpG islands.
RESULTS: CIHM pf p14 was found in 70 (47.9%) cases, in 26 (17.8%) for p16, in 104 (71.2%) for CDH1 and in 127 (87.0%) for DAPK. CIHM-high was also found in 63 cases (43.2%). No association was found between between CIHM status and different staging, Lauren's subtypes, anatomic location, venous and lymphatic invasion, lymph node metastasis, distant metastasis, or peritoneal dissemination. However, among early gastric cancer cases, the depressed type with ulceration presented a significantly lower prevalence of CIHM of DAPK. In addition, Borrmann type IV cases presented significantly lower prevalence of CIHM-high among advanced gastric cancer. The Borrmann type IV cases also presented lower mean methylation number.
CONCLUSION: The present results suggest that CIHM of DAPK and CIHM-high were associated with the morphological appearance of depressed type with ulceration in early gastric cancer, and Borrmann type IV advanced gastric cancer, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20150642

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Association between common genetic variants in pre-microRNAs and the clinicopathological characteristics and survival of gastric cancer patients.

Authors:  Masaaki Okubo; Tomomitsu Tahara; Tomoyuki Shibata; Hiromi Yamashita; Masakatsu Nakamura; Daisuke Yoshioka; Joh Yonemura; Yoshio Kamiya; Takamitsu Ishizuka; Yoshihito Nakagawa; Mitsuo Nagasaka; Masami Iwata; Tomiyasu Arisawa; Ichiro Hirata
Journal:  Exp Ther Med       Date:  2010-09-29       Impact factor: 2.447

Review 2.  The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review.

Authors:  Wei Zeng; Jinfeng Zhu; Li Shan; Zhigang Han; Patiguli Aerxiding; Amina Quhai; Fanye Zeng; Ziwei Wang; Huiwu Li
Journal:  Drug Des Devel Ther       Date:  2015-04-13       Impact factor: 4.162

3.  Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.

Authors:  Li-xia Li; Yan-ling Zhang; Ling Zhou; Miao-la Ke; Jie-min Chen; Xiang Fu; Chun-ling Ye; Jiang-xue Wu; Ran-yi Liu; Wenlin Huang
Journal:  J Transl Med       Date:  2013-10-14       Impact factor: 5.531

Review 4.  Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis.

Authors:  Wenzhuo Jia; Tao Yu; Xianglong Cao; Qi An; Hua Yang
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

5.  Gene methylation profile of gastric cancerous tissue according to tumor site in the stomach.

Authors:  Rita Kupcinskaite-Noreikiene; Rasa Ugenskiene; Alius Noreika; Viktoras Rudzianskas; Jurgita Gedminaite; Jurgita Skieceviciene; Elona Juozaityte
Journal:  BMC Cancer       Date:  2016-01-26       Impact factor: 4.430

Review 6.  Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities.

Authors:  Matteo Canale; Andrea Casadei-Gardini; Paola Ulivi; Maria Arechederra; Carmen Berasain; Pier-Luigi Lollini; Maite G Fernández-Barrena; Matías A Avila
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.